COMMITS-CAN

Start date: 22 January 2024
End date: 31 January 2028
Funder: Abbott Diabetes Care
Value: $370,000
Primary investigator: Professor Ramzi Ajjan
Co-investigators: Dr Becky Birch, Dr Katie Spencer, Dr Simon Howell
External co-investigators: Laura Ashley, Leeds Beckett University

Description

The COMMITS-CAN study is trying to understand ways in which cancer treatment (including chemotherapy, hormone therapy, immunotherapy and targeted therapy) affects glucose levels in people with type 2 diabetes.

We want to know whether glucose sensors, which measure glucose levels every minute, improve cancer outcomes by keeping glucose levels nearer the normal range. We are hoping the research in this study will help us to improve the care and outcomes of people with cancer who have type 2 diabetes.

Participants eligible for the study includes patients with breast, bowel or lung cancer who also have type 2 diabetes. The participants will be randomised to either monitoring with a Libre Freestyle device (blood glucose monitor) and support from the diabetes team or usual standard of care. Clinical outcome, glycaemic profile and quality of life will be studied.

The project will utilise Flash Continuous Glucose Monitoring to obtain continuous blood glucose readings for the individuals enrolled in the study and will link survey and routinely collected healthcare data, enabling the assessment of the relationship between granular glycaemic information and health outcomes for the first time.

The Primary Objective of the study is to test the hypothesis that the proportion of patients who complete planned pharmaceutical therapy without meaningful interruption or dose adjustment is superior with the FreeStyle Libre device (flash glucose monitoring) and enhanced diabetes support.

Four secondary objectives; 1. To assess the feasibility of using glucose profile, provided by flash glucose monitoring data, to predict adverse events over the course of cancer treatment, 2. To examine the acceptability of using the FreeStyle Libre device and LibreView in a cancer context, 3. To determine the feasibility of using a desirability of DOOR framework, 4. To determine assess the cost effectiveness of the addition of the FreeStyle Libre device and enhanced diabetes support.